复方异丙托溴铵、氨溴特罗联合治疗毛细支气管炎患儿的效果  

Combination of Compound Ipratropium Bromide and Ambroxol in the Treatment of Children with Bronchiolitis

作　　者：邓提虎[1] DENG Tihu(Department of Pediatrics,the First Affiliated Hospital of Guangxi University of Science and Technology,Liuzhou,Guangxi Zhuang Autonomous Region 545000 China)

机构地区：[1]广西科技大学第一附属医院儿科,广西柳州545000

出　　处：《世界复合医学》2021年第8期178-181,共4页World Journal of Complex Medicine

摘　　要：目的分析复方异丙托溴铵、氨溴特罗联合治疗毛细支气管炎患儿的效果。方法选择该院2018年1月—2020年2月治疗的80例患儿毛细支气管炎,根据不同治疗方案进行分组,将采用氨溴特罗治疗的患儿纳入参照组(n=40),将采用复方异丙托溴铵联合氨溴特罗治疗的患儿纳入研究组(n=40)。比较两组患儿的治疗总有效率、不良反应发生率、症状消失时间以及炎性指标[胰岛素样生长因子Ⅱ(IGF-Ⅱ)、血清降钙素原(PCT)]。结果与参照组相比,研究组总有效率较高(77.50%vs 95.00%),差异有统计学意义(χ^(2)=5.160,P<0.05)。研究组较对照组症状消失时间短,差异有统计学意义(P<0.05)。在比较不良反应发生率中,研究组与参照组相比差异无统计学意义(P>0.05)。两组治疗前的血清IGF-Ⅱ、PCT水平相比差异无统计学意义(P>0.05);两组治疗后的血清IGF-Ⅱ、PCT水平低于治疗前,且研究组血清IGF-Ⅱ、PCT水平低于参照组,差异有统计学意义(P<0.05)。结论在毛细支气管炎患儿治疗中,给予复方异丙托溴铵联合氨溴特罗药物,不仅能增强临床疗效,改善患儿临床症状,还能缓解支气管炎症反应,且用药安全性较高。Objective To analyze the effect of combined ipratropium bromide and ambroxol in the treatment of children with bronchiolitis.Methods The 80 children with bronchiolitis treated in this hospital from January 2018 to February 2020 were selected and grouped according to different treatment plans.The children treated with ambroxol were included in the reference group(n=40).Children treated with compound ipratropium bromide combined with ambroxol were included in the study group(n=40).The total effective rate of treatment,incidence of adverse reactions,time of symptom disappearance,and inflammatory indexes[insulin-like growth factor II(IGF-II),serum procalcitonin(PCT)]were compared between the two groups of children.Results Compared with the reference group,the total effective rate of the study group was higher(77.50%vs 95.00%),and the difference was statistically significant(χ^(2)=5.160,P<0.05).The symptom disappearance time of the study group was shorter than that of the control group,and the difference was statistically significant(P<0.05).In comparing the incidence of adverse reactions,there was no statistically significant difference between the study group and the reference group(P>0.05).There was no statistically significant difference in serum IGF-Ⅱand PCT levels between the two groups before treatment(P>0.05);the serum IGF-Ⅱand PCT levels after treatment in the two groups were lower than before treatment,and the study group's serum IGF-Ⅱand PCT levels were lower than the reference group,and the difference was statistically significant(P<0.05).Conclusion In the treatment of children with bronchiolitis,the administration of compound ipratropium bromide combined with ambroxol can not only enhance the clinical efficacy and improve the clinical symptoms of the children,but also relieve the bronchial inflammation,and the medication is safer.

关 键 词：复方异丙托溴铵 氨溴特罗 毛细支气管炎 胰岛素样生长因子Ⅱ 安全性 

分 类 号：R4[医药卫生—临床医学]